SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery

Stock Information for Sohm Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sohm Inc

SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery
SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development
SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea
SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility
SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement
SOHM, Inc. Appoints Ravi Kapoor as an Independent Director
SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.